Opendata, web and dolomites

BIO-CHIP SIGNED

BIOengineered grafts for Cartilage Healing In Patients (BIO-CHIP)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIO-CHIP project word cloud

Explore the words cloud of the BIO-CHIP project. It provides you a very rough idea of what is the project "BIO-CHIP" about.

healthcare    extend    preliminary    osteoarthritic    joint    treatments    disability    therapeutic    biochip    12    reference    savings    company    healing    defects    130    untreatable    animal    lesions    manufacturing    life    innovative    chondrocytes    surgery    trial    prosthetic    kissing    pain    bio    clinical    compatibility    prospected    autologous    device    reproducibly    carry    strate    size    orthopedic    model    treat    prospective    preparation    young    procedure    improves    patients    regeneration    tissues    nc    spontaneous    nasal    worldwide    chip    therapies    untreated    108    recruited    mature    maturation    demonstration    predictably    shown    treatment    indications    opportunity    significance    poor    implants    reproducible    elderly    gmp    sheep    hypothesis    generate    capacity    multicenter    cartilage    engineered    predispose    osteoarthritis    characterization    employed    function    cell    reduce    molecular    revenues    capitalizes    million    quality    restore    implantation    centers    mechanical    statistical    structure    consolidate    commercial    injuries    knee    articular    delay    grafts    efficacy   

Project "BIO-CHIP" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT BASEL 

Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051
website: www.unibas.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://biochip-h2020.eu/
 Total cost 5˙108˙273 €
 EC max contribution 3˙051˙836 € (60%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 0.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 1˙204˙593.00
3    SVEUCILISTE U ZAGREBU MEDICINSKI FAKULTET HR (ZAGREB) participant 967˙000.00
4    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 446˙931.00
5    ISTITUTO ORTOPEDICO GALEAZZI SPA IT (MILANO) participant 341˙201.00
6    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 53˙056.00
7    JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG DE (WUERZBURG) participant 39˙053.00
8    MEDACTA INTERNATIONAL SA CH (CASTEL SAN PIETRO) participant 0.00

Map

 Project objective

Spontaneous healing of articular cartilage injuries is poor and untreated defects predispose to osteoarthritis. Current therapies, including innovative autologous cell-based treatments, cannot predictably and reproducibly restore cartilage structure and function. BIOCHIP will carry out a multicenter, prospective phase II clinical trial to treat knee cartilage injuries using engineered grafts based on autologous nasal chondrocytes (NC). As compared to typically employed articular chondrocytes, NC have a higher and more reproducible capacity to generate mature cartilage tissues. Importantly, molecular/mechanical characterization, large size animal studies and a phase I trial carried out by BIOCHIP partners have already shown the compatibility of NC upon implantation in a joint, with promising preliminary clinical results. BIO-CHIP’s specific objectives are: (1) To test the hypothesis that the maturation of NC-based cartilage grafts improves the clinical efficacy in the treatment of cartilage lesions (108 patients will be recruited to reach statistical significance) (2) To extend the range of clinical indications of NC-based grafts to so far untreatable pre-osteoarthritic lesions (‘kissing’ cartilage lesions in a sheep model) BIO-CHIP capitalizes on clinical experience of 4 reference centers for cartilage surgery, on established GMP manufacturing capacity and on preparation for commercial exploitation by a strong orthopedic device company. Demonstration of therapeutic efficacy of the new treatment will address a large clinical need (over 2 million cartilage defects/year worldwide), improve quality of life (reduce pain & disability in the young, delay prosthetic implants in the elderly), exploit a commercial opportunity (prospected revenues of up to 130 million €/year) and reduce healthcare costs (estimated 12,000€ healthcare savings/procedure). BIO-CHIP will consolidate the currently leading role of Europe in the development of cell-based cartilage regeneration strate

 Deliverables

List of deliverables.
Public website Websites, patent fillings, videos etc. 2019-11-26 09:34:26

Take a look to the deliverables list in detail:  detailed list of BIO-CHIP deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Ivkovic, A.
Nose2Knee: Clinician\'s Perspective
published pages: , ISSN: , DOI:
11TH OSWESTRY CARTILAGE SYMPOSIUM 2019-11-26
2018 Ivkovic, A.
Cartilage injuries
published pages: 21-23, ISSN: , DOI:
SportsOrtho a la Carte Congress 2019-11-26
2018 Pušić, M.
Cellular communication in 3D, Regeneration of kissing cartilage lesions in the knee using autologous nasal chondrocyte-based cartilage grafts
published pages: , ISSN: , DOI:
2nd Annual Meeting, COST Action CA16119 Cellfit 2019-11-26
2018 Martin, I.
From the nose to the knee: engineered nasal cartilage for articular cartilage repair.
published pages: , ISSN: , DOI:
International Stem Cell Conference/International Placenta Stem Cell Society (IPLASS) 2019-11-26
2016 Asnaghi, M.A., Miot, S., Wixmerten, A., Martin, I
Successes and hurdles in the translation of tissue engineered products for cartilage repair in clinical trials: focus on regulatory perspectives
published pages: 172, ISSN: 1473-2262, DOI:
European Cells and Materials Vol 31, Suppl 1, 2016 2019-11-26
2019 Peren A
Studio clinico Nose to knee: il primo intervento in Italia
published pages: , ISSN: , DOI:
Tabloid Ortopedia 2019-11-26
2018 Marijanović, I.
Molecular and histological characterization of nasal chondrocyte-based cartilage grafts for the treatment of kissing lesions in the knee
published pages: 133, ISSN: , DOI:
5th Termis World Congress 2019-11-26
2017 Ivkovic, A.
Tissue Regeneration in Osteoarthritis and Tendinopathy
published pages: , ISSN: , DOI:
Artherex Congress, Subchondral Bone Healing: How to Treat? 2019-11-26
2017 Oliver Pullig
GMP for Beginners - Wasted time or new impulses for my scientific career?
published pages: , ISSN: , DOI:
TERMIS - SYIS ITN Symposium 2019-11-26
2016 Teresa Kilian
Pre-clinical evaluation of chondrocytes in a matrix based cartilage implant (German)
published pages: , ISSN: , DOI:
2019-11-26
2017 Mumme, M.
Nasal chondrocytes for articular cartilage repair: update on clinical studies.
published pages: , ISSN: , DOI:
TERMIS- EU 2017: Personalised Therapies for Regenerative Medicine 2019-11-26
2018 Lehoczky, G.
“Nose to knee”: Nasenknorpel zur Regeneration vom Gelenkknorpel
published pages: , ISSN: , DOI:
AGA Congress 2019-11-26
2017 Karoliina Pelttari, Marcus Mumme, Andrea Barbero, Ivan Martin
Nasal chondrocytes as a neural crest-derived cell source for regenerative medicine
published pages: 1-6, ISSN: 0958-1669, DOI: 10.1016/j.copbio.2017.05.007
Current Opinion in Biotechnology 47 2019-11-26
2018 Power, L.
Nondestructive Raman Spectroscopy-based quality controls for tissue engineered cartilage
published pages: , ISSN: , DOI:
TERMIS World Congress 2018 Integration of Industry, Government, and Academia for Regenerative Medicine 2019-11-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIO-CHIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIO-CHIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More